Centocor Remicade
Executive Summary
BLA submitted for infliximab Jan. 26 for the treatment of rheumatoid arthritis. The submission is based on 30-week results from the 428-patient Anti-TNF Trial in Rheumatoid Arthritis (ATTRACT), which showed a 52% reduction in signs and symptoms of RA for infliximab compared to a 20% decrease for placebo. Centocor reported Remicade sales of $27.5 mil. since approval for Crohn's disease in August 1998